reversible ATX inhibitor w/ alt. binding mode

in vivo PD observed on oral dosing

from HTS screen and opt.

Bioorg. Med. Chem. Lett., Nov. 4, 2020

Novartis, Horsham, UK / Basel, CH

“compound 15a” (Novartis reversible in vivo ATX inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks